A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

Inclusion criteria

• Japanese healthy subjects aged =>18 and <40 years at the time of obtaining informed consent
• Subjects whose body weight is >=40 kg at the screening test, and body mass index is >=18.5 and <25.0
• Subjects with both heart rates are =>45 and =<100 beats/min on a standard 12-lead electrocardiogram at the screening test and before drug administration in Period 1

Exclusion criteria

• Subjects with a history of hypersensitivity to moxifloxacin or other quinolone antibiotics
• Subjects with a family history or risk factors for aortic aneurysm or aortic dissection (e.g., Marfan syndrome)
• Subjects with a family history of sudden death
• Subjects with congenital diseases, heart diseases, or medical history of such conditions
• Subjects with risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, or a family history of long QT syndrome) or medical history of such conditions
• Subjects with medical history of syncope suspected to be related to TdP, unexplained syncope, or seizures
• Subjects with standard 12-lead electrocardiogram waveforms that make it difficult to evaluate QTc prolongation (e.g., drift, EMG interference, T wave morphology, significant sinus arrhythmia, or frequent ectopic beats) at the screening and before the administration of the study drug in Period 1
• Subjects with a QTcF (QT interval corrected using Fridericia's formula) of =>450 msec in the standard 12-lead ECG test at the screening and before the administration of the study drug in Period 1